SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Buller DB, English DR, Buller MK, Simmons J, Chamberlain JA, Wakefield M, Dobbinson S. Am. J. Public Health 2017; 107(12): 1869-1875.

Affiliation

David B. Buller and Mary Klein Buller are with Klein Buendel, Inc., Golden, CO. Dallas R. English is with the Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Jody Simmons, Melanie Wakefield, and Suzanne Dobbinson are with the Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne. James A. Chamberlain is with the Cancer Epidemiology Centre, Cancer Council Victoria.

Copyright

(Copyright © 2017, American Public Health Association)

DOI

10.2105/AJPH.2017.304071

PMID

29048958

Abstract

OBJECTIVES: To test whether shade sails will increase the use of passive recreation areas (PRAs).

METHODS: We conducted a stratified randomized pretest-posttest controlled design study in Melbourne, Australia, and Denver, Colorado, in 2010 to 2014. We randomized a sample of 144 public parks with 2 PRAs in full sun in a 1:3 ratio to treatment or control. Shade sails were built at 1 PRA per treatment park. The outcome was any use of the study PRA (n = 576 pretest and n = 576 posttest observations; 100% follow-up).

RESULTS: Compared with control PRAs (adjusted probability of use: pretest = 0.14, posttest = 0.17), use of treatment PRAs (pretest = 0.10, posttest = 0.32) was higher at posttest (odds ratio [OR] = 3.91; 95% confidence interval [CI] = 1.71, 8.94). Shade increased use of PRAs in Denver (control: pretest = 0.18, posttest = 0.19; treatment: pretest = 0.16, posttest = 0.47) more than Melbourne (control: pretest = 0.11, posttest = 0.14; shaded: pretest = 0.06, posttest = 0.19; OR = 2.98; 95% CI = 1.09, 8.14).

CONCLUSIONS: Public investment in shade is warranted for skin cancer prevention and may be especially useful in the United States. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02971709. (Am J Public Health. Published online ahead of print October 19, 2017: e1-e7. doi:10.2105/AJPH.2017.304071).


Language: en

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print